BGB-A425

DRUG3 trials

Sponsors

Beigene Ltd., Beigene Ltd., Beigene Ltd., BeiGene

Conditions

Head and Neck CancerHead and Neck Squamous Cell CancerHead and Neck Squamous Cell CarcinomaNon-Small Cell Lung CancerRenal Cell Carcinoma

Phase 1

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors

CompletedCTIS2022-500694-14-00

Beigene Ltd., Beigene Ltd.Head and Neck Squamous Cell Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma

Start: 2023-06-02End: 2025-02-06Target: 48Updated: 2025-01-31

Phase 2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Active, not recruitingNCT05909904

BeiGeneHead and Neck Cancer, Head and Neck Squamous Cell Carcinoma

Start: 2023-07-21End: 2026-05-28Target: 160Updated: 2025-10-07

A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Active, not recruitingCTIS2023-503418-63-00

Beigene Ltd.Head and Neck Squamous Cell Carcinoma

Start: 2023-11-23Target: 28Updated: 2025-07-25

Related Papers

Abstract 4041: Translational assessment of triple combination with Tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and &lt; for Surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and &lt; for clinical potential in solid tumors such as HNSCC

Cancer Research2024-03-22